Skip to main content

Table 1 Baseline patient characteristics

From: Real-life experience with benralizumab during 6 months

Parameter n = 42
Age, years (m ± sd) 53.6 ± 11
Women, n (%) 33 (78.6)
BMI (m ± sd) 28.6 ± 6
Age at diagnosis, years (m ± sd) 28.9 ± 12.6
Dyspnoea
 Degree 0–2, n (%) 20 (47.6)
 Degree 3–4, n (%) 22 (52.4)
Atopy, n (%) 14 (33)
Corticosteroid-dependent, n (%) 17 (40.5)
Nasal polyps, n (%) 12 (28.6)
AERD, n (%) 6 (14.3)
ACT (m ± sd) 13.9 ± 4.1
ED visits in the previous year (m ± sd) 4.1 ± 2.6
Cycles of OCS in the previous year, (m ± sd) 5.9 ± 3.3
Oral prednisone (or equivalent) dose, mg/day (m ± sd) 19.6 ± 9
Inhaled budesonide (or equivalent) dose, μg/day (m ± sd) 956 ± 475
Post-BD FEV1, mL (m ± sd) 1429.4 ± 475
Post-BD FEV1, % (m ± sd) 64.4 ± 9.3
FeNO, ppb (m ± sd) 61.5 ± 23.9
Blood eosinophil count, cells/μL (m ± sd) 757.2 ± 278
IgE, IU/mL (m ± sd) 228.6 ± 403
Prior treatment with a biologic agent, n (%) 22 (52.4)
 Prior omalizumab, n (%) 15 (35.7)
 Prior mepolizumab, n (%) 5 (11.9)
 Prior omalizumab + mepolizumab, n (%) 2 (4.8)
Duration of prior biologic therapy, months (m ± sd) 21.14 ± 23.8
Duration of prior omalizumab therapy, months (m ± sd) 26.2 ± 27.5
Duration of prior mepolizumab therapy, months (m ± sd) 9.8 ± 3.5
  1. Abbreviations: ACT Asthma Control Test, AERD Aspirin-exacerbated respiratory disease, BD Bronchodilator, BMI Body mass index, ED Emergency department, FeNO Fractional exhaled nitric oxide, FEV1 Forced expiratory volume in 1 s, m Mean, ppb Parts per billion, OCS Oral corticosteroids, sd Standard deviation